Polyrizon Ltd. has completed contracting for all five U.S. clinical trial sites for its NASARIX Allergy Blocker study, marking a key step toward patient enrollment. The development-stage biotech company, based in Raanana, Israel, finalized agreements with the final two sites, enabling the trial to proceed into pre-screening and enrollment preparations.
The first-in-human, multicenter trial is designed as a prospective, randomized, single-blind, two-arm study evaluating the efficacy, safety, and tolerability of NASARIX in patients with seasonal allergic rhinitis under real-world allergen exposure. Up to 120 patients will be enrolled and assigned in a 1:1 ratio to receive either NASARIX Allergy Blocker or an isotonic saline nasal spray control.
The primary efficacy endpoint will assess the difference between treatment groups in mean daily reflective Total Nasal Symptom Score over the first 14 treatment days. Secondary measures include instantaneous Total Nasal Symptom Score, rhinoconjunctivitis-related quality of life, number of symptom-free days, and use of permitted relief medication. Safety assessments will track treatment-emergent adverse events and overall tolerability.
Patient enrollment is planned to align with allergy seasons, with the company monitoring local pollen counts and weather conditions to optimize recruitment timing. NASARIX is a proprietary nasal spray designed to create a protective barrier within the nasal cavity, representing a non-drug approach to managing seasonal allergic rhinitis.
